CD8A and lung adenocarcinoma: In support of this findings, a systemic immunogenic combination chemotherapy (cyclophosphamide–oxaliplatin) in KrasLSL-G12D/+; Trp53flox/flox lung adenocarcinoma tumors leads to ICD-dependent CD8+ T-cell infiltration and synergy with ICI45.